modelCiclosporin
Extends from Pharmacolibrary.Drugs.ATC.S.S01XA18.
Information
| name: | Ciclosporin | |
| ATC code: | S01XA18 | route: | topical |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Ciclosporin (also known as cyclosporine) is a calcineurin inhibitor immunosuppressant used to prevent organ transplant rejection, and to treat certain autoimmune diseases. It is clinically approved and in use today, including topical ophthalmic formulations (ATC S01XA18) for conditions such as dry eye disease.
Pharmacokinetics
Pharmacokinetic parameters in adults after ophthalmic (eye drop) administration; limited systemic absorption expected.
References
Surber, C, et al., & Büchner, S (1992). Clinical controversy on the effect of topical ciclosporin: what is the target site?. Dermatology (Basel, Switzerland) 185(4) 242–245. DOI:10.1159/000247460 PUBMED:https://pubmed.ncbi.nlm.nih.gov/1477416
Frampton, JE, & Blair, HA (2018). Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis. American journal of clinical dermatology 19(4) 617–624. DOI:10.1007/s40257-018-0370-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30027349
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)